Topic

Oak Hill Bio

1 recent story · updated continuously

Benzinga

Oak Hill Bio Secures $32.5 Million to Propel Rugonersen Therapy for Angelman Syndrome into Phase 3 Trials

healthJust now
Oak Hill Bio Secures $32.5 Million to Propel Rugonersen Therapy for Angelman Syndrome into Phase 3 Trials